Development of molecular diagnostic of minimal residual disease ofgastric cancer in peritoneal fluids
Project/Area Number |
22591468
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Kitasato University |
Principal Investigator |
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 胃癌 / 腹水 / DNA診断 / CDO1 / メチル化 / 微小癌細胞 / HOPX / Reprimo / 腹水洗浄細胞診 |
Research Abstract |
We have identified cancer-specific methylation genes as HOPX, Reprimo, and CDO1. HOPX was not detected in peritoneal fluids of advanced gastric cancer, so we started to examine CDO1 potential for minimal residual disease. CDO1 could be detected for cancer cells with CDO1 methylation by 1/1000 dilution. Plasma of cancer patients showed poor quality of DNA, because sensitivity of beta-actin exhibitedso. DNA detection in plasma of cancer patients showed in 30% of advanced gastric cancer, shiwh is similar with classical tumor marker. So, we think that novel device is requiredfor clinical application of DNA methylation by nested PCR or acquisition of good quality DNA.
|
Report
(4 results)
Research Products
(13 results)